Granules Quarterly Results for Trading Insights
In Mar 2026, Granules (GRANULES) reported revenue ₹1,482 Cr and net profit ₹202 Cr — revenue +20.5% YoY. Browse Granules annual reports for revenue, profit, balance sheet and cash flow data.
GRANULES Quarterly Results — Revenue, Profit & EPS Highlights
Granules latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore GRANULES share price charts to track price trends across different timeframes.
- Revenue of ₹1,482 Cr in Mar 2026 (+14.5% vs Sept 2025, +20.5% vs Mar 2025)
- Net Profit of ₹202 Cr in Mar 2026 (+54.2% vs Sept 2025, +32.9% vs Mar 2025)
- EBITDA of ₹364 Cr in Mar 2026 (+32.4% vs Sept 2025)
- Operating Margin of 23.0% in Mar 2026 (+2.0pp vs Sept 2025)
- Earnings Per Share of ₹8.23 in Mar 2026 (+53.0% vs Sept 2025)
Granules Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GRANULES quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,482 | 1,294 | 1,230 | 1,225 | 1,374 | 14.5% | 20.5% |
| Net Profit (₹ Cr) | 202 | 131 | 152 | 113 | 150 | - | - |
| EBITDA (₹ Cr) | 364 | 275 | 284 | 236 | 295 | - | - |
| EPS (₹) | 8.23 | 5.38 | 6.27 | 4.64 | 6.19 | - | - |
| Operating Margin (%) | 23.0% | 21.0% | 21.0% | 18.0% | 22.0% | - | - |
GRANULES Share Price Trend — 1-Year Movement Across Quarterly Results
Granules 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Granules screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GRANULES vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Granules latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores